CD274 and neoplasm: Subgroup analyses according to the tumor PD-L1 expression level showed that anti-PD-1/PD-L1 therapy significantly improved both OS (Fig. 4) and PFS (Fig. 5) in patients with high expressions of PD-L1, but not in those with low expressions.